In response to increased resistance of malaria parasites to conventional drugs, the WHO has been promoting for the past decade artemisinin-based combination therapy (ACT) for treating uncomplicated malaria [1 ]. ACTs are now being used in over 150 malaria endemic countries. The recommended combinations are artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisininpiperaquine, artesunate-mefloquine, and artesunatesulfadoxine-pyrimethamine, the first four available as co-formulations or fixed dose combinations. The choice of an ACT in a country or region should be based on the level of resistance of the medicine partner to the artemisinin component in the combination [2 ]. Other factors to consider are acceptability, safety, tolerability, ease of adherence, availability, co-formulation, and cost [1 ,2 ].
Introduction
In response to increased resistance of malaria parasites to conventional drugs, the WHO has been promoting for the past decade artemisinin-based combination therapy (ACT) for treating uncomplicated malaria [1 ] . ACTs are now being used in over 150 malaria endemic countries. The recommended combinations are artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisininpiperaquine, artesunate-mefloquine, and artesunatesulfadoxine-pyrimethamine, the first four available as co-formulations or fixed dose combinations. The choice of an ACT in a country or region should be based on the level of resistance of the medicine partner to the artemisinin component in the combination [2 ] . Other factors to consider are acceptability, safety, tolerability, ease of adherence, availability, co-formulation, and cost [1 ,2 ] .
Efficacy and effectiveness of artemisininbased combination therapy
Arteminisin, originally isolated from the Chinese wormwood Artemisia annua, is extremely potent against chloroquine and sulphadoxine-pyrimethamine-resistant P. falciparum. It clears malaria parasites faster than other antimalaria drugs [3 ] . Its three bioavailable semi-synthetic derivatives, artemether, artusunate, and dihydroartemisinin, have short half-lives and are combined with longeracting antimalarials to form the most effective antimalaria drugs currently available [1 ,2 ,3 ]. ACTs have higher cure rates, faster parasite clearance, and decreased gametocyte carriage compared with monotherapy [1 ,2 ,3 ].
Practice conditions. It is the most widely adopted ACT regimen in African malaria control programs. Artemetherlumefantrine is approved for the treatment of uncomplicated malaria in adults, children and infants, and in nonimmune travelers. Artemether-lumefantrine is efficacious for treating uncomplicated malaria in children and the frequency of associated adverse events is not higher than other available ACT regimens [4 ] . Artemetherlumefantrine demonstrates cure rates above 90%, even in areas of multiple drug resistance [2 , [5] [6] [7] . After its introduction, over 250 million treatments of artemetherlumefantrine have not revealed any new safety concerns apart from hypersensitivity and allergies, known class effects of artemisinin derivates [8 ] . The most common regimen is a 3-day twice a day dosing scheme; administration recommended with fatty food necessary to assist lumefantrine absorption.
Results from Africa indicate that combinations of artesunate-amodiaquine and artesunate þ sulphadoxinepyrimethamine are highly effective, although efficacy may be compromised in areas with moderate to high levels of resistance to sulphadoxine-pyrimethamine and amodiaquine. In randomized comparative trials, the crude efficacy of artesunate-amodiaquine was 75.9% [9 ] . Artesunate-amodiaquine compares well with other treatments and meets the WHO efficacy criteria for use against P. falciparum malaria in many, but not all, the sub-Saharan African countries where it was studied [9 ,10,11] . A new fixed-dose combination is safe and efficacious even in children under 5 years of age. A once-a-day intake of this new combination appears effective in the treatment of uncomplicated P. falciparum malaria in both adults and children [12 ] . Concerns have been raised about the possibility of neutropenia in patients following repeated treatment with amodiaquinecontaining combination. One study in Uganda found an increased rate of neutropenia in HIV-infected children treated for malaria with artesunate-amodiaquine [13] .
Dihydroartemisinin-piperaquine has proved to be a safe, well tolerated, and highly effective treatment of P. falciparum malaria in Asia and Africa, with efficacy over 95% [14 ,15 ] . Dihydroartemisinin-piperaquine is as efficacious as artemether-lumefantrine in treating uncomplicated malaria in African children from different endemicity settings, and shows a comparable safety profile [16 ] . It has an added advantage because it has a longer posttreatment prophylactic effect [16 ] . Other studies have similarly shown high efficacy with dihydroartemisininpiperaquine. The drug is well tolerated with no obvious drug-associated adverse events [17] [18] [19] . The treatment efficacy of three different ACT regimens from a series of randomized clinical trials conducted in different transmission settings in Uganda is shown in Table 1. The results show that dihydroartemisinin-piperaquine was superior to artemether-lumefantrine and artesunateamodiaquine for reducing the risk of recurrent parasitemia and recrudescence. Dihydroartemisinin-piperaquine thus appears to be a good alternative to artemether-lumefantrine and artesunate-amodiaquine as first-line treatment of uncomplicated malaria in Uganda.
ACTs containing slowly eliminated partner drugs such as piperaquine or mefloquine exert a greater post-treatment prophylactic effect against additional infection and relapse compared with more rapidly eliminated partner drugs, such as lumefantrine [17, 20] . The clinical benefit of this transient additional protection lies in delaying the next recurrence. Patients have longer periods free of symptomatic malaria, allowing a greater time for hematologic recovery, which in turn reduces the cumulative risk of anemia, an important cause of malaria morbidity [20] . On the other hand, prolonged exposure to long-acting partner drugs could lead to the development of resistance, blunting the long-term effectiveness of a subclass of ACTs.
Treatment with ACTs significantly reduces infectiousness of individual patients with uncomplicated P. falciparum malaria [3 ,21] . They are more effective against gametocytes than previous first-line antimalarials and therefore have the potential to reduce parasite transmission. ACTs have the potential for transmission reductions approaching those achieved by insecticide-treated nets in lower transmission settings [22] . Eliminating the source of transmission by mass treatment of human populations in malaria-endemic areas using an ACT and primaquine has been experimented within Cambodia and reduced parasite rates from 52.3% to 2.6% after 3 years [23 ] .
Acceptability of artemisinin-based combination therapy
Parental perceptions of the efficacy and side-effects of ACT regimens have been favourable. In Tanzania, community members spoke favourably of ACTs, emphasizing their ability to help children to rapidly recover from malaria, without undesirable side-effects [24] . Similarly in Ghana, a majority of parents reported an increase in rapidity of symptom resolution, compared with their previous experience of other childhood malaria therapies, and with parents of children treated with monotherapy Health workers, knowledge and attitudes, the availability of malaria diagnostics and drugs, and the balancing of concurrent medical conditions are just some of the factors that may lead clinicians to prescribe alternative treatments [26] [27] [28] [29] [30] [31] [32] [33] . More effort is needed to inform healthcare workers and to provide them with the resources necessary for effective malaria case management.
Access to artemisinin-based combination therapy
For effective treatment to reach greater numbers of people in need, the distribution of ACTs should be supported in ways that respond to specific needs of individual countries. The models currently proposed to achieve improved ACT distribution include scaling up public sector provision of healthcare and subsidizing drugs provided through the private sector.
ACTs should be available at a cost that every family can afford and close enough for any sick person to obtain promptly. By 2009, 77 of 81 malaria-endemic countries and territories had adopted ACTs for use in their national drug policy (Fig. 1) . Sixty countries are deploying these medicines in the general health services, with varying levels of coverage [34 ] . Access to ACTs is poor in African countries, with fewer than 15% of children under 5 years of age receiving an ACT when they have fever [34 ] .
In many malaria-endemic countries, weak and/or poorly distributed public health systems and inconsistent supply chains limit access to ACT via the public sector. Similarly, private sector pricing of ACTs is currently too high for most families in sub-Saharan Africa to afford.
Other challenges in the artemisinin-based combination therapy era
National malaria control and elimination programs face many challenges in providing ACT, including increasing the use of malaria diagnostics, integrating ACT in home management of malaria (HMM), addressing the lack of effective second-line therapy, and providing appropriate pediatric drug formulations.
Malaria diagnostic testing
Malaria diagnostic testing is increasingly advocated in resource-limited settings to promote cost-effective use of ACTs. The WHO 2010 malaria treatment guidelines recommend parasitological confirmation by either microscopy or rapid diagnostic tests (RDTs) whenever possible [1 ]. However, the proportion of patients treated for malaria who have a confirmed diagnosis is still low in Africa compared with other regions of the world. Consequently, antimalarials are commonly used to treat patients without malaria [35 ] . The continued presumptive treatment of fever in areas of decreasing malaria transmission leads to missed or delayed diagnosis of the true underlying disease and unnecessary costs due to overtreatment with expensive ACTs, and may contribute to the spread of resistance. While there have not been reports of ACT resistance in Africa, in-vivo reduced susceptibility to artesunate has been reported in Cambodia [36 ] . Increasing access to diagnostic testing is a necessary step in providing successful disease management in malaria-endemic areas [32] .
Home malaria management
In areas with high malaria transmission and limited access to health facilities, HMM, in which families receive antimalarials to presumptively treat febrile illnesses, has played an increasing role in malaria control efforts [37 ] . Implementation research is needed to develop appropriate HMM strategies in the ACT era [37 ].
Provision of ACT at the community level has increased access to high-risk groups living in underserved areas. A multicountry study in Ghana, Nigeria, and Uganda showed that the proportion of febrile children who received prompt treatment and the correct dose for the assigned duration of treatment ranged from 71% to 87% [38] . The use of RDTs, through community health workers, in the context of HMM has been studied in a number of settings. The cost-effectiveness of a 'test-andtreat' strategy for the home-based management of malaria (based on an artemisinin-combination therapy) was compared with that of a 'treat-all' strategy in an area of high malaria transmission in southern Mali [39 ] . Use of RDTs was not cost-effective compared with the presumptive treatment of malaria with an ACT [39 ] .
By contrast, a randomized trial of ACT-based HMM without diagnostic testing in the capital of Uganda found that HMM led to significant over-treatment, higher costs, and only modest health benefits [40 ] . The authors concluded that HMM without diagnostic testing may not be appropriate for urban areas with significant access to health facilities and fairly low malaria transmission [40 ] . Furthermore, in Sudan, the use of RDTs improved the level of accuracy and trust in the diagnosis; however, 30% of volunteers did not rely on the negative RDT results when treating fever cases [41] . These studies suggest that the appropriate approach to HMM will need to be tailored to local conditions and that one size fits all policies are unlikely to work, even at the national level.
Second-line therapy
The WHO recommends alternative locally effective ACT regimens and 7 days of artesunate or quinine plus tetracycline, doxycycline, or clindamycin as second-line therapies for P. falciparum malaria [1 ]. Most sub-Saharan African countries have trouble maintaining adequate supplies of one recommended ACT and do not have adequate supplies of tetracyclines or clindamycin. Therefore, many countries currently recommend quinine monotherapy as second-line therapy [42 ] . In these countries, providers faced with low supplies of ACTs use 7-day courses of oral quinine monotherapy as a firstline alternative for uncomplicated malaria [42 ] .
A recent randomized control trial comparing artemetherlumefantrine with quinine monotherapy was stopped due to clear superiority of artemether-lumefantrine (cure rate 96 vs. 64% for artemether-lumefantrine and quinine, respectively, hazard ratio 10.7; 95% CI 3.3-35.5; P ¼ 0.001) [42 ] . The authors found significantly higher rates of nonadherence for the 7-day quinine regimen compared with the 3-day artemether-lumefantrine regimen [42 ] . This study highlights the lack of an appropriate policy for second-line drugs for the treatment of uncomplicated malaria in much of sub-Saharan Africa.
There is an urgent need to strengthen and broaden drug supplies to include the requirements for second-line treatment [43] . In addition, as quinine is widely available throughout sub-Saharan Africa, providing the apprioprate partner drugs would also provide effective secondline therapy [44] .
Paediatric formulations of artemisinin-based combination therapies
Administering ACTs to infants and small children can be difficult and time-consuming. Specially formulating antimalarials for this vulnerable population is vital to ease Treating uncomplicated malaria in children Yeka and Harris 801 administration and help ensure that an accurate dose is received. Most antimalaria tablets need to be crushed and mixed with water or food for infants and young children.
They have a bitter taste, which may result in children spitting the medicine out and not receiving the full therapeutic dose. Dispersible artemether-lumefantrine was developed and has shown excellent efficacy, safety, and tolerability [45 ] . Easing administration may foster adherence, improving therapeutic outcomes in infants and young children and preserving the efficacy of ACTs [45 ,46] .
Conclusion
ACTs are an essential tool in the fight to control and eliminate malaria. They are currently the most effective drugs against P. falciparum malaria. They should be deployed through programs that address availability, cost, adherence, and quality assurance. Initiatives including HMM, improving public sector procurement and supply chains, and reducing private sector pricing should make ACT more accessible. Further implementation research is needed on new approaches for the large-scale deployment of ACTs. In addition, more basic and clinical research is needed to search for cheaper and more effective therapeutic agents.
